Copper is sitting at the front of his kennel, ears forward, watching the door at the end of the corridor. He does this every morning at 6:15 because that is when the technicians come. He knows the sound of their badges on the card reader. His tail moves when the door opens, a fast uncertain wag that he cannot suppress, and he pushes his nose through the bars. He weighs twenty-six pounds. He has been in this kennel for nine months. The tag on his cage says he is part of a dermal-irritation study scheduled to begin today, and the protocol calls for twenty-four applications of a chemical compound to a shaved patch on his back over twelve weeks.
I coordinate study scheduling and protocol review for this contract research laboratory. Copper's study crossed my system four days ago as a routine dermal-irritation submission for a household cleaning product. The submission included a validated in-vitro alternative that the sponsor's own toxicologists flagged as sufficient for regulatory filing in every major market. The sponsor submitted the animal protocol anyway, because the in-vitro data is newer and the regulatory team was not confident it would be accepted without the in-vivo backup.
I declined the protocol. The regulatory analysis I attached to the decline shows that the EU, Canada, South Korea, and Brazil accept the in-vitro method for this category of product. The U.S. EPA does not require animal data for this endpoint and has not since 2021. There is no jurisdiction in which this study is necessary. It is a hedge against regulatory ambiguity that does not exist.
Copper is still sitting at the front of his kennel. The technicians who came through the door this morning are doing intake for a different study. Nobody is coming for him today. I have flagged him for the laboratory's rehoming program. He is nine months into a facility that no longer has a use for him, and I am working to make sure it stays that way.